Side-by-side comparison of AI visibility scores, market position, and capabilities
Epigenetic protein engineering company developing liquid biopsy detection tools for the $50B blood test market; backed by Harvard's George Church competing in cancer early detection diagnostics.
Epinoma is a San Francisco-based biotech company engineering proteins that read and write epigenetic signals — developing protein tools for earlier cancer and disease detection through liquid biopsy (blood tests that detect disease-specific epigenetic marks) and therapeutic interventions that modify epigenetic states to treat disease without permanently altering DNA sequence. A Y Combinator S21 graduate backed by George Church (Harvard genetics pioneer), seedToB, and SeaX Ventures with $125,000 raised, Epinoma achieved $1 million in revenue in 2024 with an 8-person team, targeting the $50 billion blood test development market.
Dominant browser-based collaborative UI design platform at ~$600M ARR and $12.5B valuation; Adobe's $20B acquisition blocked by regulators in 2023, Figma remains independent competing with Sketch and Adobe.
Figma is a San Francisco-based collaborative web-based product design platform that has become the dominant tool for UI/UX designers and product teams — enabling real-time multi-user collaboration on interface design, prototyping, and design system management directly in the browser without installing desktop software. Founded in 2012 by Dylan Field and Evan Wallace and backed by Sequoia, Greylock, and Andreessen Horowitz with over $330 million raised, Figma generated approximately $600 million in ARR in 2023, serving 4 million+ designers and product teams at companies including Microsoft, Airbnb, Twitter, and Uber. Adobe announced a $20 billion acquisition offer in 2022, which was blocked by regulators in 2023 — Figma remains independent.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.